Laureate Pharma Announces $9 Million Expansion of Manufacturing Facility in Princeton

		Laureate Pharma, Inc. is a contract manufacturing and services company dedicated to supporting the commercialization of products for pharmaceutical and biopharmaceutical companies. The company has locations in Princeton and Totowa, NJ. The company provides services to develop "well characterized" biopharmaceutical products and sustained release microsphere products and carries them through process development, validation and cGMP production. For more information on Laureate Pharma, contact the company directly at 609-919-3400, by email at info@laureatepharma.com or visit www.laureatepharma.com. (PRNewsFoto) PRINCETON, NJ USA

Employment to Top 90 by Year-end PRINCETON, N.J., June 8 /PRNewswire/ -- Laureate Pharma, a partner company of Safeguard Scientifics (NYSE: SFE), today announced plans to invest up to $9 million to expand its biopharmaceutical manufacturing facility in Princeton, NJ. (Logo: http://www.newscom.com/cgi-bin/prnh/20020723/LPHARMLOGO ) The facility expansion will provide Laureate Pharma with a new pilot production plant with two separate production suites and expanded purification production capacity to support additional cGMP production. The new pilot plant will include stainless steel stirred tank bioreactors and disposable single-use bioreactors -- the same technologies used in Laureate's large-scale cGMP biomanufacturing facility. The pilot plant is designed for process development, production and purification of early-phase preclinical proteins and is isolated from Laureate's main manufacturing area. New equipments to be installed include bioprocess purification systems, analytical testing systems and associated equipment. Employment at Laureate is expected to grow by 15% by year-end, in response to increased demand. Laureate is recruiting additional professional and technical staff to supplement its existing teams. The job postings can be found on the Laureate web site -- http://www.laureatepharma.com. "2006 has been a very strong year for Laureate Pharma," said Robert Broeze, PhD, Laureate's President and CEO. "In anticipation of continued growth, we are significantly increasing our development and manufacturing capacity to meet our clients' current and future needs." "This expansion will enable Laureate Pharma, our partner company, to accommodate increased customer demand for protein-based biopharmaceutical products, without disruption to ongoing customer projects," said James Datin, Executive Vice President and Managing Director, Life Sciences of Safeguard Scientifics. Construction on the expansion has already started, with completion of the pilot production suites targeted for the end of 2006. The additional cGMP capacity is expected to be operational in mid-2007. Laureate's primary engineering firm for the project is CE&IC of Burlington, NJ. About Laureate Pharma, Inc. Laureate Pharma, located in Princeton, NJ, is a full-service biopharmaceutical development and protein Production Company that provides superior bioprocessing services from process design and development to full- scale cGMP production of monoclonal antibodies and recombinant proteins. Laureate Pharma, Inc. is a partner company of Safeguard Scientifics. For more information, please contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com. About Safeguard Safeguard Scientifics, Inc. (NYSE: SFE) builds value in high-growth, revenue stage information technology and life sciences businesses by providing growth capital, strategic, operational and management resources. For additional information, visit http://www.safeguard.com.